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RESEARCH ARTICLE Open Access
White blood cell DNA methylation and risk
of breast cancer in the Prostate, Lung,
Colorectal, and Ovarian Cancer Screening
Trial (PLCO)
Susan R. Sturgeon1*, J. Richard Pilsner2, Kathleen F. Arcaro3, Kaoru Ikuma4,5, Haotian Wu2, Soon-Mi Kim4,
Nayha Chopra-Tandon1, Adam R. Karpf6, Regina G. Ziegler7, Catherine Schairer7, Raji Balasubramanian1
and David A. Reckhow4
Abstract
Background: Several studies have suggested that global DNA methylation in circulating white blood cells (WBC) is
associated with breast cancer risk.
Methods: To address conflicting results and concerns that the findings for WBC DNA methylation in some prior
studies may reflect disease effects, we evaluated the relationship between global levels of WBC DNA methylation in
white blood cells and breast cancer risk in a case-control study nested within the Prostate, Lung, Colorectal and
Ovarian Cancer Screening Trial (PLCO) cohort. A total of 428 invasive breast cancer cases and 419 controls,
frequency matched on age at entry (55–59, 60–64, 65–69, ≥70 years), year of entry (on/before September 30, 1997,
on/after October 1, 1997) and period of DNA extraction (previously extracted, newly extracted) were included. The
ratio of 5-methyl-2’ deoxycytidine [5-mdC] to 2’-deoxyguanine [dG], assuming [dG] = [5-mdC] + [2’-deoxycytidine
[dC]] (%5-mdC), was determined by liquid chromatography-electrospray ionization-tandem mass spectrometry, an
especially accurate method for assessing total genomic DNA methylation.
Results: Odds ratio (OR) estimates and 95% confidence intervals (CI) for breast cancer risk adjusted for age at entry,
year of entry, and period of DNA extraction, were 1.0 (referent), 0.89 (95% CI, 0.6–1.3), 0.88 (95% CI, 0.6–1.3), and 0.
84 (95% CI, 0.6–1.2) for women in the highest compared to lowest quartile levels of %5md-C (p for trend = .39).
Effects did not meaningfully vary by time elapsed from WBC collection to diagnosis.
Discussion: These results do not support the hypothesis that global DNA hypomethylation in WBC DNA is
associated with increased breast cancer risk prior to the appearance of clinical disease.
Keywords: Breast cancer, White blood cells, Global DNA methylation, %5mdC, Cohort
Background
Cytosines can be methylated in the mammalian genome,
primarily at CpG sites. CpG sites are located throughout
the genome, including gene promoter regions and re-
petitive DNA sequences. DNA methylation patterns play
a key role in gene expression and cell integrity. For
example, genome-wide hypomethylation can be associ-
ated with chromosomal instability and the expression of
oncogenes or repetitive sequences that are normally si-
lenced by methylation [1]. Global loss of DNA methyla-
tion is characteristic of cancer tissue [2].
There are several different methods to assess global DNA
methylation. Measurement of the ratio of 5-methyl-2’
deoxycytidine [5-mdC] to 2’-deoxyguanine [dG], assuming
[dG] = [5-mdC] + [2’-deoxycytidine [dC]] (%5-mdC), by
liquid chromatography-electrospray ionization-tandem
mass spectrometry (LC-ESI-MS/MS) provides a
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comprehensive measure of genome-wide DNA methyla-
tion levels [3]. This method is considered the gold stand-
ard as it evaluates the entire genome but is expensive and
time-consuming, and requires specialized laboratory
equipment. Approximately one-third of the DNA methy-
lation in the genome occurs in the repetitive sequences of
the genome, including LINE-1 and Alu [4]. For this rea-
son, DNA methylation levels in LINE-1 or Alu repeats,
which can be obtained by high-throughput methods, have
often been used as surrogate markers of global DNA
methylation [5]. Other high-throughput surrogate
methods for estimating global methylation are available.
For example, the luminometric methylation assay
(LUMA) [6] estimates global DNA methylation levels by
using restriction enzymes specific for methylated and
unmethylated CCGG, a sequence found throughout the
genome. A different approach has been to average methy-
lation levels across the limited set of individual CpG sites
represented on the Illumina human methylation bead kits
[7, 8]. An advantage of this latter approach, relative to
aggregrate methods of assessing global methylation (e.g.,
%5mdC, LINE-1), is that one can adjust for potential dif-
ferences in blood cell composition between cases and con-
trols in archived blood specimens [9]. A second advantage
is that it is possible to conduct subanalyses to examine
methylation in specific locations in the genome (e.g., pro-
moter regions across the genome) [7, 8].
Global DNA hypomethylation of breast tumor tissue is
well-established [2]; however, there is some evidence
that global hypomethylation in circulating white blood
cell (WBC) DNA may also be associated with an in-
creased risk of breast cancer. One possible explanation
is that the association represents unidentified environ-
mental and lifestyle determinants that influence both
global methylation and breast cancer risk. An alternative
possibility is that, in response to very early, preclinical
breast cancer, a new clone of circulating leukocytes
arises that alters white blood cell DNA methylation [10].
In a relatively small retrospective case-control study,
Choi and colleagues [11] observed a nearly threefold in-
crease in breast cancer risk among women in the lowest
tertile of %5-mdC in WBC DNA compared to women in
the highest tertile. Comparable results were obtained
prospectively in the case-cohort study nested in the
NIEHS Sister Cohort Study [12], with a nearly twofold
increased risk observed among women in the lowest
quartile of LINE-1 WBC DNA methylation compared with
those in the highest quartile. By contrast, a number of other
investigations, including three separate nested case-control
studies from Europe, which used pre-diagnostic DNA (and
were presented in a single publication) [13], observed no
association between LINE-1 methylation in WBC DNA
and breast cancer risk [11, 13–18] or between Alu methyla-
tion in WBC DNA and breast cancer risk [14, 16, 19].
Findings from the three retrospective case-control studies
employing the LUMA assay were inconsistent, with posi-
tive, inverse, and null associations [15, 20, 21]. However,
three of the four nested case-control studies, which used
the Illumina HumanMethylation450 BeadChip on prediag-
nostic DNA (separate results from three cohorts were re-
ported in a single paper [8]) observed that global
hypomethylation was positively associated with increased
breast cancer risk [7, 8].
To address these discrepant results, we examined the
association between global hypomethylation in WBC
DNA and subsequent breast cancer incidence in a study
nested in the Prostate, Lung, Colorectal and Ovarian
Cancer Screening (PLCO) Trial cohort. We measured
WBC DNA %5-mdC levels by LC-ESI-MS/MS because:
(1) WBC global hypomethylation as measured by %5-mdC
level was found to be strongly and significantly associated
with increased breast cancer risk in the one breast cancer
study that measured %5-mdC, which was a relatively small
restrospective study [11]; (2) global hypomethylation as
measured by WBC DNA %5-mdC was reported to be
more strongly associated with overall cancer risk than sur-
rogate measures of global methylation (LINE-1, Alu, and
LUMA) in a recent meta-analysis [22]; and (3) %5-mdC
level measured by LC-ESI-MS/MS is considered the gold
standard assay for accurately assessing methylation across
the entire genome.
Our study is important because it is the first invest-
igation to examine the association between WBC DNA
%5-mdC levels, measured prior to breast cancer diagno-
sis, and subsequent breast cancer incidence. In this large
study of 428 cases and 419 controls, the elapsed time be-
tween blood collection and breast cancer development
ranged from 1.0 to 9.5 years, enabling us to examine
whether risk varied by time elapsed between blood col-
lection and diagnosis.
Methods
Selection of study subjects
Cases and controls for the present analysis were selected
from the Etiology and Early Marker Study (EEMS)
breast cancer case-control study that was established
from the 39,115 women randomized to the intervention
arm of the PLCO screening trial [23]. Through June 30,
2005, a total of 1141 eligible cases of breast cancer were
identified. A total of 1141 controls were frequency
matched to cases by randomly sub-sampling women
who had not been diagnosed with breast cancer by June
30, 2005 in eight strata defined by four age categories
(55–59, 60–64, 65–69, ≥70 years) and time of entry into
the study (on/before September 30, 1997, on/after
October 1, 1997).
A total of 732 cases and 928 controls were initially iden-
tified as eligible for the present analysis, after further
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excluding in the following order: subjects who did not give
permission for genetic studies (cases = 32, controls = 25),
subjects who had a personal history of any cancer prior to
the trial (cases = 40, controls = 30), subjects with uncon-
firmed, erroneous or in situ breast cancer (cases = 229,
controls = 13), subjects who developed other types of can-
cer anytime during follow up (cases = 105, controls = 130),
and other reasons (cases = 3, controls = 14).
A total of 649 out of the 726 cases and 787 out of the
928 controls either had: (1) DNA already extracted from
buffy coat/whole blood remaining from a prior study; or
(2) buffy coat available for extraction. We further
excluded 83 breast cancer cases in which diagnosis
occurred within one year of the DNA collection, to
minimize the likelihood of disease effects, leaving an
eligible pool of 566 cases and 787 controls.
For efficiency, our a priori plan was to select 430
cases and 430 controls for this analysis. We first pri-
oritized case selection to include the 151 cases and
147 controls that already had DNA extracted as part
of another study [24]. We then supplemented study
subject selection to include cases and controls with
buffy coat available for DNA extraction for this study.
Controls were frequency matched to cases on age,
calendar year of entry, and the date of the DNA ex-
traction (already extracted DNA or newly extracted
DNA). Matching on date of DNA extraction was
done to address the possible concern that DNA
methylation patterns may be affected by the timing or
method of DNA extraction. We ultimately selected
428 breast cancer cases and 420 controls that had
suitable DNA for analysis, slightly less than our goal
because some of the subjects we originally selected
turned out to have inadequate DNA. One additional
control subject was later excluded for an improbable
value for %5-mdC (67.4%). Thus, our final analysis
consisted of 428 cases and 419 controls. The institu-
tional review boards of the National Cancer Institute,
the 10 participating study centers, and the University
of Massachusetts Amherst approved this study. In-
formed consent was obtained from all participants at
study enrollment.
DNA extraction
For 298 study subjects, DNA was previously extracted in
2006–2007 from stored buffy coat (98%) or whole blood
(2%). About 90% of this DNA was extracted using the
Autopure method (Qiagen) and the remaining speci-
mens were extracted using standard phenol/chloroform
extraction. In 2014, DNA was extracted for the
remaining study subjects using the QIAsymphony SP
automated extraction robot (Qiagen). DNA concentra-
tions were quantified using the Picogreen assay and
nanodrop technology.
DNA hydrolysis
To provide individual nucleosides for subsequent total
methylated cytosine measurements, genomic DNA were
hydrolyzed with DNA Degradase Plus (Zymo Research,
Cat # E2021) following the manufacturer’s protocol with
minor adjustments. Briefly, 400 ng of genomic DNA was
incubated with 5 U of DNA Degradase Plus in 25 μl
total reaction volumes at 37 °C for 2 hours. Batch con-
trol DNA included female genomic DNA (Promega, Cat
# G1521), which was considered to be “normally” meth-
ylated. Complete DNA hydrolysis of additional control
samples were verified by agarose gel electrophoresis. Hy-
drolyzed DNA samples were stored at −20 °C until %5-
mdC analyses.
Measurement of %5-mdC
The %5-mdC levels were determined by LC-ESI-MS/MS
after hydrolysis of DNA as described by Song and col-
leagues [3], with modifications. Both 5-mdC and dG
concentrations were quantified with internal standard
additions of isotope-labeled 5-mdC and dG (5-mdC-d3
and 15 N5-dG, respectively; obtained from Toronto
Research Chemicals). LC separation was performed on
an Acquity UPLC system (Waters Corporation) at a flow
rate of 400 μL/min. Methanol containing 0.1% formic
acid and water containing 0.1% formic acid were used as
buffers. The organic buffer ratio was increased at a linear
gradient from 0 to 22.5% over 8 min for the elution of
nucleosides. The sample injection volume was 20 μL.
Detection by ESI-MS/MS was performed on a Quattro
Premier XE Mass Spectrometer (Waters Corporation)
following LC separation. The following optimized condi-
tions for ESI positive ion mode were used: source
temperature, 120 °C; desolvation gas flow, 700 L/h; cone
gas flow, 50 L/h; capillary voltage, 4.2 kV; cone voltage,
10 V; extractor voltage, 2 V; entrance potential voltage,
0 V; collision energy, 11 V; and collision cell exit poten-
tial, 2.0 V. Multiple reaction monitoring mode was
utilized for the quantification of native and labeled nu-
cleosides. The transition pairs of molecular and fragment
ions monitored were m/z 242.0/126.0 for 5-mdC, m/z
245.0/129.0 for 5-mdC-d3, m/z 268.1/152.0 for dG, and
m/z 273.0/157.0 for 15 N5-dG with a scan time of
150 minutes for each pair. Following QuanLynx (Waters
Corporation) analysis for chromatographic peak detec-
tion, the resulting peak areas of the native nucleosides
were normalized to the labeled internal standards and
quantified based on external calibration curves. The 5-mdC
and dG nucleosides for external calibration were obtained
from Fisher Scientific. We took the average of two
injections from each sample vial. Results are reported
as the ratio between 5-mdC and dG, assuming that
[dG] = [5-mdC] + [dC]. Laboratory personnel were blinded
to case status.
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Samples were run on twelve plates, with cases and
controls distributed on each plate approximately evenly
within eight stratum defined by age and time of entry.
Each plate had DNA that was either all pre-extracted or
all newly extracted. On each plate, we also included
three replicate DNA specimens from three women who
were in a study site for the PLCO trial that was later
dropped (newly extracted DNA). The mean inter-batch
coefficient of variation across the twelve plates for each
of the three women was 8, 7, and 9%, respectively. The
female genomic DNA average inter-batch coefficient of
variation was comparable at 9.2%.
In Fig. 1, we show levels of %5-mdC for study subjects
in each of the twelve batches and also separately for
cases and controls in each batch. Levels of %5-mdC
varied by batch and showed limited variation across
individuals within batch.
Breast cancer ascertainment
Breast and other cancers were primarily identified through
an annual study update mailed to participants, which
established cancer diagnosis in the previous year, including
type and date [25]. Non-respondents were contacted by
mail and telephone. In order to confirm the self-reported
cancers, medical records (for standardized medical record
abstraction of pathology reports) were retrieved and usu-
ally obtained within 2 years of self-report. Cancers were
also identified through death certificates, data obtained
from state cancer registries, and information from next-of-
kin for deceased participants.
Ascertainment of other variables
Demographic information, medical history, and health-
related behavior were obtained through baseline ques-
tionnaires completed by study participants at or around
the time of randomization.
Statistical analysis
Logistic regression was used to estimate odds ratios and
95% CI, for breast cancer with case/control status as the
outcome and a categorical variable denoting quartiles of
the %5-mdC levels as the primary exposure of interest.
Fig. 1 Boxplot distribution of the ratio of 5-methyl-2’ deoxycytidine (5-mdC) to 2’-deoxyguanine (dG) (%5-mdC) levels by case-control status in
each of twelve laboratory plates. The ends of the boxes are the 25th and 75th percentiles and the center line is the median. The lengths of the
whiskers are defined as 1.5*(75th percentile – 25th percentile). The circles are values outside the whisker length
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Because of the evidence of inter-batch variation, we cre-
ated %5-mdc quartile levels separately for each batch
and then created a new summary variable with four
levels based on the batch-specific cut points. For ex-
ample, individuals in the lowest category of the summary
variable included individuals from each of the twelve
batches who were placed in the lowest batch-specific
quartile ranking. Models were adjusted for matching var-
iables, including age in four categories (55–59, 60–64,
65–69, ≥70 years), time of entry into the study (on/before
September 30, 1997, on/after October 1, 1997), and period
of DNA extraction (previously extracted, newly extracted).
Additional models considered adjustment for established
or suspected breast cancer risk factors, including race,
body mass index, age at menarche, age at first live birth,
number of children, type of menopause, age at natural
menopause, personal history of benign breast disease,
cigarette smoking, recent alcohol intake, family history of
breast cancer, and menopausal hormone use. Statistical
significance was assessed for each level of the primary ex-
posure variable using two-sided Wald hypothesis tests.
Results
Relative risks for established breast cancer risk factors
were generally comparable in our analytic subgroup of
cases and controls to those reported previously in the lit-
erature [25] (Table 1). Nulliparity, later age at first birth,
late age at natural menopause, a personal history of be-
nign breast disease, a family history of breast cancer, and
alcohol consumption were associated with increased
breast cancer risk. Late age at menarche, three or more
live births and surgical menopause were associated with
reduced breast cancer risk.
The batch-standardized quartile distribution of %5-mdC
was unrelated to the distribution of breast cancer risk fac-
tors or study design matching factors (Table 2).
As shown in Table 3, odds ratios and 95% CI, adjusted
for age and time of entry and period of DNA extraction,
were 1.0 (referent), 0.89 (95% CI, 0.6–1.3), 0.88 (95% CI,
0.6–1.3), and 0.84 (95% CI, 0.6–1.2) comparing women
in the highest to the lowest batch-specific quartile levels
of %5-mdC (p for trend = .39). Results were essentially
unchanged after additional adjustment for breast cancer
risk factors (p for trend = .35). When we restricted ana-
lyses to 298 cases who were hormone-receptor-positive
(estrogen-receptor-positive and progesterone-receptor-
positive) and 419 controls, comparable fully-adjusted
odds ratios and 95% CI were similar: 1.0, 0.82 (0.5–1.3),
0.98 (0.6–1.5), and 0.85 (0.5–1.3) (data not shown).
In further analyses, we stratified on period of DNA
extraction (Table 4). Among the group with previously
extracted DNA, we observed a nonsignificant increase
(OR = 1.44, 95% CI, 0.8–2.7) in risk in the lowest quartile
of %5-mdC compared to those in highest quartile. In the
group with newly extracted DNA, however, there was an
unexpected decreasing trend in the ORs from the
highest to lowest quartile of %5-mdC (p for trend = .05).
Risk was also significantly decreased in the lowest quar-
tile of %5-mdC compared to those in the highest quartile
(OR = 0.61, 95% CI, 0.40–1.0).
We further stratified on both period of DNA extraction
and elapsed time from blood collection to diagnosis. In-
herent to the study design, all of the breast cancer cases
diagnosed within 1- < 2 years of blood collection had pre-
viously extracted DNA. When we restricted the analysis to
study subjects with previously extracted DNA, we ob-
served nonsignificant slight increases in risk in the lowest
quartile level of %5-mdC in all three categories of years
since blood collection (i.e. 1- < 2, 2- < 4, ≥4 years). When
we restricted analysis to study subjects with newly ex-
tracted DNA, however, we found no evidence of any in-
creased risk in women in either the 2- < 4, or ≥4 years
since blood collection.
Discussion
Overall, we found no evidence that lower levels of %5-mdC
in white blood cell DNA were associated with increased
breast cancer risk in a case-control study nested in the
PLCO cohort. The %5mdC assay provides a comprehensive
measure of genome-wide DNA methylation and is consid-
ered the gold standard for accuracy. Odds ratio (OR) esti-
mates and 95% confidence intervals (CI) for breast cancer
risk adjusted for age at entry, year of entry, and period of
DNA extraction, were 1.0 (referent), 0.89 (95% CI, 0.6–1.3),
0.88 (95% CI, 0.6–1.3), and 0.84 (95% CI, 0.6–1.2) for
women in the highest compared to lowest quartile levels of
%5md-C (p for trend = .39). There was some variability in
our results depending on whether the DNA was previously
or newly extracted. We observed a nonsignificant increased
risk in the lowest quartile of %5mdC in the subset of
women with previously extracted DNA, whereas risk was
significantly decreased in the lowest quartile of %5mdC in
the subset of women with newly extracted DNA. One pos-
sibility is that this difference in the results by period of
DNA extraction is the result of technical issues or sample
degradation. Conceivably, the earlier method of extraction
or shorter buffy coat storage of the previously extracted
samples may have resulted in less non-differential misclassi-
fication in our methylation measure. In a recent reliability
study of methylation measures from mononuclear cells
using the HumanMethylation450K Bead Array, differences
in DNA extraction methods (and possible differences in cell
composition resulting from them) were suggested to have
contributed to lower observed reliability for repeated sam-
ples across studies than for technical replicates within a
study [26]. Given that our findings that previously and
newly extracted DNA were in opposing directions and that
there was a larger sample size of newly extracted DNA,
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Table 1 Associations between demographic and lifestyle characteristics and risk of breast cancer, adjusted for age and time of entry
into the cohort
Controls % Cases % Odds Ratio, 95% CI
Age (years)
<59 150 35.8 151 35.3 1.0 (referent)
60–64 140 33.4 141 32.9 1.00 0.72 1.39
65–69 93 22.2 102 23.8 1.09 0.76 1.56
> =70 36 8.6 34 7.9 0.94 0.56 1.58
Time of entry
> =October 10, 1997 168 40.1 174 40.7 1.0 (referent)
< =September 30, 1997 251 59.9 254 59.4 1.02 0.78 1.35
Race
White, non-Hispanic 380 90.7 395 92.3 1.0 (referent)
Other 39 9.3 33 7.7 0.81 0.50 1.32
Body mass index (kg/m2)
Underweight-normal (15–24.99) 175 41.9 176 41.2 1.0 (referent)
Overweight (25.0–29.99) 141 33.7 152 35.6 1.07 0.79 1.46
Obese (> = 30) 102 24.4 99 23.2 0.96 0.68 1.36
Age at menarche (years)
<12 70 16.8 88 20.6 1.0 (referent)
12–13 238 56.9 219 51.2 0.73 0.51 1.05
> =14 110 26.3 121 28.3 0.87 0.58 1.31
Number of live births
None 31 7.4 48 11.2 1.0 (referent)
1–2 births 123 29.4 147 34.4 0.77 0.46 1.29
3+ births 265 63.3 233 54.4 0.57 0.35 0.92
Age at first birth (years)
<20 72 17.2 55 12.9 1.0 (referent)
20–24 209 49.9 181 42.5 1.14 0.76 1.70
25–29 80 19.1 108 25.4 1.77 1.12 2.79
> =30 27 6.4 34 8.0 1.66 0.89 3.07
Nulliparous 31 7.4 48 11.3 2.03 1.14 3.59
Type of menopause
Natural 253 60.4 283 66.1 1.0 (referent)
Bilateral oophorectomy 49 11.7 29 6.8 0.52 0.31 0.85
Other 117 27.9 116 27.1 0.88 0.65 1.20
Age at natural menopause (years)
<50 91 36.0 95 33.7 1.0 (referent)
50–54 122 48.2 141 50.0 1.15 0.79 1.69
55+ 40 15.8 46 16.3 1.15 0.69 1.93
History of benign breast disease
No 285 69.9 261 61.9 1.0 (referent)
Yes 123 30.2 161 38.2 1.43 1.07 1.91
Smoking status
Never 257 61.3 229 53.5 1.0 (referent)
Former 135 32.2 163 38.1 1.36 1.02 1.82
Current 27 6.4 36 8.4 1.51 0.89 2.56
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chance due to small numbers after stratification is a likely
explanation for the observed variability.
Our results are not consistent with those of the one
other breast cancer study to measure global DNA hypo-
methylation with %5-mdC, a small case-control study in
which WBC DNA was collected after breast cancer diag-
nosis [11]. In that study, risk of breast cancer was nearly
three times higher among those with in the lowest tertile
of %5-mdC compared to those in the highest tertile. A
major strength of our study is that we purposely in-
cluded only breast cancer cases in which DNA was col-
lected at least 12 months prior to diagnosis. We found
no evidence that risk varied according to time elapsed
between blood collection and breast cancer diagnosis.
As well-summarized in a recent systematic review
[27], the weight of evidence also does not support an as-
sociation between breast cancer risk and WBC DNA
methylation, measured in other studies by surrogate
marker methods, such as Alu, LINE-1, or LUMA. Of
seven retrospective case-control studies [11, 14–19] and
four studies with prospectively collected pre-diagnostic
WBC DNA (results from three cohorts were presented
in a single publication) [12, 13] that measured global
methylation by Alu and LINE-1 methylation, only one
[12] observed a significantly higher risk of breast cancer
among those who had lower LINE-1 methylation levels.
Three retrospective case-control studies have examined
the relation between WBC DNA global methylation
levels and breast cancer risk using LUMA, with incon-
sistent results [15, 20, 21]. As suggested by Brennan and
colleages [22], LINE-1 and other surrogate assays are
likely not sufficiently sensitive to detect slight inter-
individual differences in WBC DNA methylation. Indeed,
Brennan and colleagues reported that the population vari-
ability in WBC DNA LINE-1 methylation measured by py-
rosequencing in prospectively collected blood did not
statistically exceed that of technical duplicates [13]. Further,
Tang and colleagues [27] noted that the findings from
WBC DNA methylation studies that have evaluated LINE-1
and breast cancer have been null with one exception,
despite using different methods of detection (e.g., combined
bisulfite restriction analysis, pyrosequencing, MethylLight).
Interestingly, a particular strength noted of the prospective
study that detected a statistical association between WBC
DNA LINE-1 hypomethylation and breast cancer risk was
that it employed three independent bisulfite conversions,
PCR, and pyrosequencing reactions on each sample [12]. In
our prospectively collected blood specimens, we also ob-
served limited population variability in %5mdC levels in
WBC DNA, adding to concern that even a small amount
of laboratory error is problematic in studies that involve
quantification of global WBC DNA methylation from
healthy individuals.
Several recent studies have estimated global methylation
by averaging individual CpG site-specific methylation levels
over the hundreds of thousands of CpG sites on the
Illumina HumanMethylation450 BeadChip [7, 8]. This al-
ternative approach measures less than 5% of the 28 million
CpG sites in the genome [28]. In two prospective cohort
analyses that used this approach to measure WBC DNA
methylation, women in the highest quartile of methylation
had about a 50% decrease in risk of breast cancer compared
to women in the lowest quartile of methylation [7, 8]. An-
other cohort analysis, which used pooled samples and next-
generation sequencing of the overlapping CpG sites from
the Illumina HumanMethylation450 BeadChip, also found
higher levels of genome-wide methylation in controls than
in cases [7]. However, findings from a fourth cohort study
were null [7]. Subanalyses based on genomic region have
been inconsistent. One study found that WBC epigenome-
wide methylation in the promoter region was associated
with an increase in breast cancer risk whereas epigenome-
wide methylation outside the promoter region was associ-
ated with a decreased risk of breast cancer [8]. A second
study confirmed that WBC epigenome-wide methylation in
gene bodies was associated with decreased risk but was un-
able to replicate the increase in risk with promoter region
methylation [7]. These findings may need to be interpreted
Table 1 Associations between demographic and lifestyle characteristics and risk of breast cancer, adjusted for age and time of entry
into the cohort (Continued)
Recent alcohol intake
No 112 29.2 99 24.9 1.0 (referent)
Yes 272 70.8 298 75.1 1.25 0.91 1.72
Family history of breast cancer
No 353 85.9 340 81.0 1.0 (referent)
Yes 58 14.1 80 19.1 1.43 0.99 2.07
Hormone user
Never 111 26.7 102 23.9 1.0 (referent)
Former 70 16.8 55 12.9 0.86 0.55 1.34
Current 235 56.5 269 63.2 1.26 0.91 1.75
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Table 2 Baseline distribution of study design and lifestyle risk factors by quartile of DNA methylationa
Q4 (high) Q3 Q2 Q1 (low)
N % N % N % N % p value
Age at entry (years)
<59 85 39.5 67 31.5 76 37.3 73 34.0
60–64 66 30.7 79 37.1 60 29.4 76 35.4
65–69 46 21.4 48 22.5 52 25.5 49 22.9
> =70 18 8.4 19 8.9 16 7.8 17 7.9
0.75
Time at entry
< =September 30,1997 134 62.3 125 58.7 114 55.9 132 61.4
> =October 1, 1997 81 37.7 88 41.3 90 44.1 83 38.6
0.53
Date of DNA extraction
Pre-extracted DNA 69 32.1 69 32.4 70 34.3 90 41.9
Newly-extracted DNA 146 67.9 144 67.6 134 65.7 125 58.1
0.12
Race/ethnicity
White, non-Hispanic 194 90.2 197 92.5 190 93.1 194 90.2
Other 21 9.8 16 7.5 14 6.9 21 9.8
0.60
Body mass index (kg/m2)
Underweight-normal (15–24.9) 77 35.8 84 39.4 98 48.3 92 43.0
Overweight (25.0 − 29.9) 91 42.3 72 33.8 60 29.6 70 32.7
Obese (> = 30) 47 21.9 57 26.8 45 22.2 52 24.3
0.09
Age at menarche (years)
<12 37 17.3 44 20.7 31 15.2 46 21.4
13 116 54.2 122 57.3 107 52.5 112 52.1
> =14 61 28.5 47 22.1 66 32.5 57 26.5
0.26
Number of live births
None 18 8.4 20 9.4 16 7.8 25 11.6
1–2 66 30.7 65 30.5 66 32.4 73 34.0
> =3 131 60.9 128 60.1 122 59.8 117 54.4
0.75
Age at first birth (years)
<20 36 16.8 32 15.0 24 11.8 35 16.3
20–24 101 47.2 94 44.1 100 49.3 95 44.2
25–29 47 22.0 54 25.4 48 23.7 39 18.1
> =30 12 5.6 13 6.1 15 7.4 21 9.8
Nulliparous 18 8.4 20 9.4 16 7.9 25 11.6
0.56
Type of menopause
Natural 129 60.0 136 63.9 126 61.8 145 67.4
Bilateral oophorectomy 20 9.3 21 9.9 17 8.3 20 9.3
Other 66 30.7 56 26.3 61 29.9 50 23.3
0.67
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with caution given a recent report that measurement error
and limited variability in DNA methylation measures from
mononuclear cells is problematic for a substantial propor-
tion of of CpG sites on the HumanMethylation450 Bead-
Chip [26].
Another potential limitation of our study is that we
studied %5-mdC in a composite of DNA from different
types of white blood cells. As previously noted by others
[29, 30], the WBC distribution can vary across individ-
uals and the level of global DNA methylation can vary
by cell type. The study by Choi and colleagues also used
composite DNA [11] as have nearly all other prior WBC
methylation studies because it is simple and yields the
most DNA [30]. Another potential limitation of our
study is the batch-to-batch variation in %5mdC that we
observed. This issue necessitated creating quartile cut
points for %5mdC separately for individuals within each
laboratory batch, a method also employed in the case-
control study by Choi and colleagues [11].
Table 2 Baseline distribution of study design and lifestyle risk factors by quartile of DNA methylationa (Continued)
Age at natural menopause (years)
<50 53 41.1 46 33.8 41 32.8 46 31.7
50–54 56 43.4 69 50.7 66 52.8 72 49.7
55+ 20 15.5 21 15.4 18 14.4 27 18.6
0.65
History of benign breast disease
No 133 62.7 143 69.4 130 64.4 140 66.7
Yes 79 37.3 63 30.6 72 35.6 70 33.3
0.51
Smoking status
Never 115 53.4 118 55.4 115 56.4 138 64.2
Former 81 37.7 78 36.6 72 35.3 67 31.2
Current 19 8.8 17 8.0 17 8.3 10 4.7
0.31
Recent alcohol intake
No 45 22.6 54 28.0 56 29.6 56 28.0
Yes 154 77.4 139 72.0 133 70.4 144 72.0
Family history of breast cancer
No 169 81.3 180 86.1 168 83.2 176 83.0
Yes 39 18.8 29 13.9 34 16.8 36 17.0
0.60
Hormone use
Never 61 28.6 51 23.9 55 27.1 46 21.6
Former 32 15.0 33 15.5 24 11.8 36 16.9
Current 120 56.3 129 60.6 124 61.1 131 61.5
0.54
aMissing values for cases and controls, respectively, were as follows: body mass index (1, 1), age at menarche (1, 0), number of livebirths (0, 2), age at
first birth (0, 3), personal history of benign breast disease (11, 6), alcohol intake (35,31), family history of breast cancer (8, 8), and hormone use (2, 3).
Q quartile
Table 3 Quartile level of WBC DNA methylation and risk of
breast cancer
Quartiles of DNA methylation
Q4 (high) Q3 Q2 Q1 (low)
Adjusted ORa 1.0 (referent) 0.89 0.88 0.84
95% CI (0.6–1.3) (0.6–1.3) (0.6–1.2)
Cases, controls 114, 101 107, 106 102, 102 105, 110
Fully adjusted ORb 1.0 (referent) 0.90 0.87 0.83
95% CI (0.6–1.3) (0.6–1.3) (0.6–1.2)
Cases, controls 114, 101 107, 106 102, 102 105, 110
WBC white blood cells, Q quartile, OR Odds Ratio
aAdjusted for age, time of entry and date of DNA extraction (previously
extracted, newly extracted)
bAdditionally adjusted for race, body mass index, age at menarche, age at first
live birth, number of children, type of menopause, age at natural menopause,
personal history of benign breast disease, cigarette smoking, alcohol intake,
family history of breast cancer, and hormone use
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Conclusions
In summary, our study, as well as the published litera-
ture, which has used a range of methods for assessing
global methylation, including Alu, LINE-1, LUMA, and
%5-mdC assays, does not support a link between WBC
DNA methylation and breast cancer risk. It is conceiv-
able a more accurate and precise measure of global
methylation is needed. However, if there is an associ-
ation between WBC DNA methylation patterns and
breast cancer risk, it is likely that the at-risk methylation
pattern is more complex and restricted to specific
regions and will need to be identified through
measures of sequence-specific or gene-specific DNA
methylation [13, 31].
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Quartiles of DNA methylation
Q4 (high) Q3 Q2 Q1 (low)
Period of DNA extraction
Previously extracted DNA
Adjusted ORa 1. 0 (referent) 0.99 1.01 1.44
95% CI (0.5–1.9) (0.5–2.0) (0.8–2.7)
Cases, controls 33, 36 33, 36 34, 36 51, 39
Newly extracted DNA
Adjusted ORa 1.0 (referent) 0.84 0.82 0.61
95% CI (0.5–1.3) (0.5–1.3) (0.4–1.0)
Cases, controls 81, 65 74, 70 68, 66 54, 71
Time from blood collection to diagnosis
Previously extracted DNA
1 to <2 years
Adjusted ORa,b 1.0 (referent) 0.99 1.16 1.41
95% CI (0.4–2.7) (0.4–3.0) (0.6–3.6)
Cases, controls 11, 36 10, 36 13, 36 16, 39
2 to <4 years
Adjusted ORa,b 1.0 (referent) 1.15 1.00 1.39
95% CI (0.5–2.7) (0.4–2.4) (0.6–3.2)
Cases, controls 14, 36 16, 36 14, 36 21, 39
≥ 4 years
Adjusted ORa,b 1.0 (referent) 0.89 0.97 1.53
95% CI (0.3–2.8) (0.3–3.1) (0.6–4.3)
Cases, controls 8, 36 7, 36 7, 36 14, 39
Newly extracted DNA
2 to <4 years
Adjusted ORa,b 1. 0 (referent) 0.88 0.73 0.68
95% CI (0.5–1.5) (0.4–1.3) (0.4–1.2)
Cases, controls 43, 65 43, 70 32, 66 33, 71
≥4 years
Adjusted ORa,b 1.0 (referent) 0.80 1.00 0.51
95% CI (0.4–1.5) (0.6–1.8) (0.3–1.0)
Cases, controls 38, 65 31, 70 36, 66 21, 71
aAdjusted for age and time at entry
bSame controls are used for each category of elapsed time from blood
collection to diagnosis, within period of DNA extraction (previously extracted,
newly extracted); OR Odds Ratio
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